Insulin Therapy & Vascular Function : Logic for New Approaches to Diabetes Care: A Translational and Evidence-Based Practice Interpretation Stan Schwartz.

Slides:

Advertisements

Similar presentations

Kenneth Cusi, MD, FACP, FACE Professor of Medicine

Advertisements

Pediatric Endocrine Metabolic Clinic

Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure.

JARDIANCE: Newly Approved Drug to Lower HbA1C in Type-2 diabetes

Lifestyle Medicine 101 Presented by ACLM Professionals in Training Executive Board 2014.

Therapy of Type 2 Diabetes Mellitus: UPDATE

Diabetes Clinical and Translational Research: Rewards and Challenges Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research.

Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.

Obesity Management: Lifestyle Modification/Bariatric Surgery.

IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.

Communicating VAD Information for Patient Decisions Larry Allen, MD, MHS INTERMACS Annual Meeting May 5, 2014.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.

Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.

IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM (Part 1) Stan Schwartz MD, FACP, FACE.

Edward P. Sloan, MD, MPH, FACEP Ischemic Stroke Patient Care: tPA Use in 2007.

Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Therapy of Type 2 Diabetes Mellitus: UPDATE

IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM (Part 2) Stan Schwartz MD, FACP, FACE.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.

Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.

Diagnosing Diabetes Mellitus in Adults: Type 1, LADA, Type 2 Stanley Schwartz MD, FACE, FACP Affiliate, Main Line Health System Emeritus, Clinical Assoc.

The Tallock Family Team Raja Jaber, MD Lynette Dias, PhD Gerardo Mackenzie, PhD Margaret McNurlan, PhD Berrin Monteleone, MD Igor Kravets, MD Jules Cohen,

Rheumatology Mastery in Ankylosing Spondylitis

What Is the Disease of Obesity?

VCU Pauley Heart Center:

Avoid Early Insulin Therapy (except in Ketosis-prone) Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Blood glucose rises.

Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.

LSU School of Medicine-New Orleans (LSUSOM-NO) is the provider of Continuing Medical Education for this activity. The planning and presentation of all.

A Clinical-Translator’s Point-of-View:

Unified Theory of Diabetes and All Its Complications

Oncology Grand Rounds “Potentially Lethal Prostate Cancer:

Working Groups (thematic description)

Therapy of Type 2 Diabetes Mellitus: UPDATE

Istanbul Medeniyet University

Speaker Presentation Title if Different than Overall Session:

Hypertension Update: How Low Shall We Go?

Achieving Excellent Control of Hyperglycemia in Critical Care and Surgery, Safely: Continuous Glucose Monitoring: Does it Have a Future in the Hospital.

National Diabetes Strategy

A Unifying Pathophysiologic Approach to The Complications of Diabetes in the Context of the Beta-cell Classification of Diabetes: A Framework for Understanding.

In Metabolic Syndrome Hyperinsulinism Creates the Vicious Cycle: Increased MAP-kinase pathway Circulation. 2005;111: Metabolic Syndrome A Comprehensive.

The β-Cell Centric Classification of DM

Beta-Cell Classification of Diabetes and the Egregious Eleven: Logic for Newer Algorithms/ Processes of Care The Role of Newer Anti-Diabetes Medications.

Results of Our Disease Management: Incomplete Success

Approved Session Title - (32pt Bold Arial)

The Future Use of Technology in Outpatient Care Using the Computerized Patient Record to Implement Principles of Disease Management: Focus on the.

Therapy of Type 2 Diabetes Mellitus: UPDATE

CHD RISK Glycemia 75g OGTT Time Metabolic Syndrome

Diabetes research update: GGC MCN meeting 5th February 2019

Approved Session Title (32pt Bold Arial)

Presenter Disclosure Information (SAMPLE DISCLOSURE SLIDE)

Presentation transcript:

Insulin Therapy & Vascular Function : Logic for New Approaches to Diabetes Care: A Translational and Evidence-Based Practice Interpretation Stan Schwartz MD, FACP, FACE Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. Medicine Univ of Pa. stschwar@gmail.com

In compliance with the accrediting board policies, the Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Stanley Schwartz Research Support: 0 Employee: 0 Board Member/Advisory Panel: Janssen, Merck, AZ-BMS, BI-Lilly, Salix, Novo, Genesis Biotechnology Group Stock/Shareholder: Saturn EMR Decision Support APP. Consultant: NIH RO1 DK085212, Struan Grant PI Other: Speaker’s Bureaus: Janssen, Merck, Novo, Salix, BI-LILLY, Eisai, AZ-Int’l, Amgen

Is Insulin Beneficial for the Vasculature (and the Patient) or NOT ??

Normal Physiology of Insulin re: The Vasculature; Counteracting Transient Oxidative Stress of Feeding Dandona P, Aljada A, Mohanty P. Diabetologia. 2002 Jun;45:924-30.

At Normal Insulin Concentrations: Benefits on Vasculature Many Still use as argument for Early Insulin Therapy in Diabetes BUT!! Circulation. 2005;111:1448-1454. Metabolic Syndrome A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation, Paresh Dandona

Even Dandona appreciated the Adverse Effects of Insulin At Abnormal Insulin Concentrations- Hyperinsulinism : Adverse Effects on Vasculature Even Dandona appreciated the Adverse Effects of Insulin Circulation. 2005;111:1448-1454. Metabolic Syndrome A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation,Paresh Dandona

Balance of Insulin Effects Mechanisms of Disease: pathway-selective insulin resistance and microvascular complications of diabetes Per-Henrik Groop*, NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM DECEMBER 2005 VOL 1 NO 2